Breaking News Instant updates and real-time market news.

YOGA

YogaWorks

$0.77

-0.135 (-15.00%)

, TCS

Container Store

$8.47

-0.07 (-0.82%)

18:49
05/14/19
05/14
18:49
05/14/19
18:49

Fly Intel: After Hours Movers

UP AFTER EARNINGS: YogaWorks (YOGA) up 20.7%... Container Store (TCS) up 14.6%... Tilray (TLRY) up 5.0%... OncoCyte (OCX) up 2.8%... Amdocs (DOX) up 0.6%. ALSO HIGHER: Legg Mason (LM) up 0.9% after WSJ speculation the company may be target of activist action by Trian. DOWN AFTER EARNINGS: Sunworks (SUNW) down 27.0%... Agilent (A) down 9.4%... Fortuna Silver Mines (FSM) down 8.0%... New Relic (NEWR) down 4.3%... 8x8 (EGHT) down 4.1%. ALSO LOWER: Virtu Financial (VIRT) down 6.3% after equity offering... JinkoSolar (JKS) down 5.9% after equity offering... Western Asset Mortgage (WMC) down 4.7% after equity offering. Movers as of 18:30ET.

YOGA

YogaWorks

$0.77

-0.135 (-15.00%)

TCS

Container Store

$8.47

-0.07 (-0.82%)

TLRY

Tilray

$48.53

2.12 (4.57%)

OCX

OncoCyte

$4.32

0.1 (2.37%)

DOX

Amdocs

$53.43

0.08 (0.15%)

LM

Legg Mason

$34.67

1.415 (4.26%)

SUNW

Sunworks

$1.27

0.03 (2.42%)

A

Agilent

$75.98

2.13 (2.88%)

FSM

Fortuna Silver Mines

$2.86

-0.065 (-2.22%)

NEWR

New Relic

$106.89

3.94 (3.83%)

EGHT

8x8, Inc.

$23.73

0.245 (1.04%)

VIRT

Virtu Financial

$24.30

-0.56 (-2.25%)

JKS

JinkoSolar

$17.71

0.3 (1.72%)

WMC

Western Asset Mortgage

$10.57

0.045 (0.43%)

  • 14

    May

  • 14

    May

  • 14

    May

  • 14

    May

  • 14

    May

  • 14

    May

  • 14

    May

  • 14

    May

  • 14

    May

  • 14

    May

  • 15

    May

  • 15

    May

  • 15

    May

  • 21

    May

  • 21

    May

  • 28

    May

  • 29

    May

  • 30

    May

  • 30

    May

  • 31

    May

  • 03

    Jun

  • 04

    Jun

  • 05

    Jun

  • 06

    Jun

  • 06

    Jun

  • 13

    Nov

  • 15

    May

  • 15

    May

  • 15

    May

YOGA YogaWorks
$0.77

-0.135 (-15.00%)

04/04/19
IMPC
04/04/19
NO CHANGE
Target $2
IMPC
Outperform
YogaWorks price target lowered to $2 from $3.50 at Imperial Capital
Imperial Capital analyst George Kelly lowered his price target for YogaWorks to $2 from $3.50 but maintains an Outperform rating on the shares following last week's Q4 results. The company's operational pressures appear to be easing "somewhat," and it will have options to address its funding needs, Kelly tells investors in a research note. With $11M in net cash, the analyst estimates YogaWorks has runway until mid-2020 "barring any changes to its operating or investment strategy."
08/20/18
COWN
08/20/18
DOWNGRADE
COWN
Market Perform
YogaWorks downgraded to Market Perform from Outperform at Cowen
Cowen analyst Oliver Chen downgrade YogaWorks to Market Perform from Outperform as he sees risk to visitation and revenue trends with the company's medium-term priorities of pulling back on promotions and marketing. Although he believes the company is doing the right thing for their long-term health, the stock valuation could be sideways for awhile, said Chen, who removed his previous $7 price target on YogaWorks shares.
08/20/18
08/20/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Constellation Brands (STZ, STZ.B) downgraded to Negative from Neutral at Susquehanna with analyst Pablo Zuanic citing valuation. 2. Infosys (INFY) downgraded to Equal Weight from Overweight at Morgan Stanley with analyst Parag Gupta citing a belief that concerns around senior management exits will remain an overhang on the stock. 3. YogaWorks (YOGA) downgraded to Market Perform from Outperform at Cowen with analyst Oliver Chen saying he sees risk to visitation and revenue trends with the company's medium-term priorities of pulling back on promotions and marketing. 4. News Corp. (NWSA) downgraded to Underweight from Equal Weight at Morgan Stanley with analyst Andrew McLeod saying its Australian payTV unit, Foxtel, will launch a new OTT sports service by the end of 2018, which presents the "obvious risk" that its existing subscriber base and high ARPU will come under pressure. 5. Park Hotels & Resorts (PK) downgraded to In Line from Outperform at Evercore ISI. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/29/18
IMPC
08/29/18
NO CHANGE
Target $3.5
IMPC
Outperform
YogaWorks has options, Street being too pessimistic, says Imperial Capital
Imperial Capital analyst George Kelly is surprised by the market reaction to YogaWorks' Q2 results earlier this month. While the results were disappointing, the 40% share decline and resulting $3M enterprise value "takes too myopic a view" of the company's outlook and strategy, Kelly tells investors in a research note. He believes "management has more options that appear little appreciated by the Street, options that would help drive scale without major dilution." The consensus view is that YogaWorks' cash burn will continue indefinitely, forcing management into a dilutive equity offering or risky financing, Kelly contends. He believes, however, that management has other options that could drive shareholder value. Other boutique brands could be interested in merging with YogaWorks, Kelly contends. Further, the analyst thinks YogaWorks' financial profile and brand "would be attractive to a larger fitness/leisure operator." He finds the Street too pessimistic on the stock and keeps an Outperform rating on the name with a $3.50 price target.
TCS Container Store
$8.47

-0.07 (-0.82%)

10/31/18
JPMS
10/31/18
DOWNGRADE
Target $6
JPMS
Underweight
Container Store downgraded to Underweight with $6 target at JPMorgan
JPMorgan analyst Christopher Horvers downgraded Container Store to Underweight from Neutral with a $6 price target. The analyst expects the 2019 consumer environment to "soften with housing appearing to moderate as well." This will disproportionately impact Container Store given the "halo impact of expected less robust brick and mortar traffic" at destination retailers, Horvers tells investors in a research note. He also expects promotions and online mix to remain headwinds while the company is set to anniversary the initial rollout of its cost savings program that began one year ago.
10/31/18
10/31/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Electronic Arts (EA) downgraded to Neutral from Overweight at Atlantic Equities with analyst Kunaal Malde saying "Live Services slowed again, contrary to our prior expectations." 2. Qualcomm (QCOM) downgraded to Neutral from Buy at BofA/Merrill with analyst Tal Liani saying Qualcomm is facing licensing disputes with Huawei and Apple (AAPL) with resolution timing uncertain and royalty rates that are likely trend lower over time. 3. Container Store (TCS) downgraded to Underweight from Neutral at JPMorgan with analyst Christopher Horvers saying he expects the 2019 consumer environment to "soften with housing appearing to moderate as well." 4. Clovis (CLVS) downgraded to Neutral from Overweight at JPMorgan with analyst Cory Kasimov saying the company's Q3 report was "clearly surprising and disappointing," as Rubraca sales of $22.8M fell well below consensus of $31.3M and represented a sequential decline versus $23.8M in Q2. 5. Weatherford (WFT) downgraded to Neutral from Buy at Guggenheim with analyst Sasha Sanwal citing the company's Q3 results. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/31/18
JPMS
10/31/18
DOWNGRADE
Target $6
JPMS
Underweight
Container Store downgraded to Underweight from Neutral at JPMorgan
JPMorgan analyst Christopher Horvers downgraded Container Store to Underweight with a $6 price target.
TLRY Tilray
$48.53

2.12 (4.57%)

05/13/19
AGPP
05/13/19
INITIATION
Target $50
AGPP
Neutral
Tilray initiated with a Neutral at Alliance Global Partners
Alliance Global Partners analyst Aaron Grey initiated Tilray with a Neutral rating and $50 price target, stating that he thinks the stock's current valuation fairly values the company's leading position in terms of the medical market and clinical trials against its lower market share versus other top Canadian licensed producers. Grey estimates Tilray to have about 5% share of the total market following the first quarter of adult-use sales. Its market share will need to increase in order to justify the stock's premium valuation, but Grey thinks catching up in terms of market share could prove difficult, he said.
05/03/19
05/03/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Domtar (UFS) upgraded to Buy from Neutral at Goldman Sachs with analyst Brian Maguire saying the current valuation on the stock marks an attractive entry point. 2. Kirby (KEX) upgraded to Buy from Underperform at BofA/Merrill with analyst Ken Hoexter stating shares have been under pressure due to overcapacity in the barging market. 3. Walmart (WMT) upgraded to Outperform from Market Perform at Bernstein with analyst Brandon Fletcher saying that while he thinks Walmart has not been able to return to its full potential for decades, the fully realized vision of what Walmart could be is "so fantastic that, if it even accidentally leans in the right direction," it could create an outsized investment return over several years. 4. Seagate (STX) upgraded to Buy from Hold at Argus with analyst Jim Kelleher stating the company looks to be "closer" to the end of the downturn in its end markets and he expects its "revitalized portfolio" to be well positioned once demand recovers. 5. Tilray (TLRY) upgraded to Hold from Underperform at Jefferies with analyst Owen Bennett saying that while he remains cautious on Tilray's outlook, "this now appears to be much better appreciated by the market" at current valuation levels. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/03/19
JEFF
05/03/19
UPGRADE
Target $57
JEFF
Hold
Jefferies upgrades Tilray to Hold but remains cautious on outlook
Jefferies analyst Owen Bennett upgraded Tilray to Hold from Underperform while lowering his price target for the shares to $57 from $61. The stock closed yesterday at $60.23. The analyst says that while he remains cautious on Tilray's outlook, "this now appears to be much better appreciated by the market" at current valuation levels. He believes the company's headwinds are now better understood, which warrants a Hold rating.
05/03/19
JEFF
05/03/19
UPGRADE
Target $57
JEFF
Hold
Tilray upgraded to Hold from Underperform at Jefferies
Jefferies analyst Owen Bennett upgraded Tilray to Hold from Underperform while lowering his price target for the shares to $57 from $61.
OCX OncoCyte
$4.32

0.1 (2.37%)

01/29/19
LSCM
01/29/19
NO CHANGE
Target $7
LSCM
Buy
OncoCyte price target raised to $7 from $4 at Lake Street
Lake Street analyst Thomas Flaten said OncoCyte's (OCX) R&D Validation study results are in line with previously published data and better than requirements for commercialization. He noted that a company-sponsored survey of 250 chest physicians previously indicated they would require minimum sensitivity and specificity of 85% and 35%, respectively. Flaten believes the fact that the study results were generated solely on biomarkers creates a favorable competitive advantage relative to competitors Veracyte (VCYT) and BioDesix, he added. Stating that he thinks today's results provide strong evidence the company can move forward with a commercially viable product, Flaten raised his price target to $7 from $4 and keeps a Buy rating on OncoCyte shares.
02/13/19
02/13/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. OncoCyte (OCX) initiated with an Overweight at Piper Jaffray. 2. SilverCrest Metals (SILV) initiated with an Outperform at BMO Capital. 3. Galectin Therapeutics (GALT) initiated with a Buy at B. Riley FBR. 4. Clovis (CLVS) initiated with a Buy at H.C. Wainwright. 5. Geron (GERN) initiated with a Buy at BTIG. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
02/13/19
PIPR
02/13/19
INITIATION
Target $6
PIPR
Overweight
OncoCyte initiated with an Overweight at Piper Jaffray
Piper Jaffray analyst William Quirk started OncoCyte with an Overweight rating and $6 price target. The company is developing a potentially best in class assay for lung cancer diagnosis, Quirk tells investors in a research note. He believes OncoCyte's test offers superior specificity compared with competitive assays and anticipate Centers for Medicare and Medicaid Services reimbursement as soon as late 2020.
02/11/19
LSCM
02/11/19
NO CHANGE
Target $7
LSCM
Buy
OncoCyte on 'stronger financial footing' after capital raise, says Lake Street
Lake Street analyst Thomas Flaten views OncoCyte's $35M capital raise positively saying it bolsters the company's balance sheet in preparation for commercialization and continuing research and development. The analyst believes OncoCyte is now on "stronger financial footing" and he keeps a Buy rating on the shares with a $7 price target.
DOX Amdocs
$53.43

0.08 (0.15%)

12/11/18
JPMS
12/11/18
NO CHANGE
Target $70
JPMS
Neutral
Amdocs can exceed mid-term growth forecasts, says JPMorgan
JPMorgan analyst Jackson Ader kept his Neutral rating and $70 price target on Amdocs after its Analyst Day, saying the company's forecasts were "an excellent reminder of the consistency in execution" of its strategy. The analyst states that Amdocs' margins and 3-year forecasts for organic revenue growth of 2%-6% were in line with expectations, but he also believes that "there are enough growth drivers in the business to produce numbers ahead of the mid-point." Ader further cites the company's lack of exposure to the slowdown in China, the potential of its "direct to consumer" move in media, and the return from its 5G investment.
01/28/19
BARD
01/28/19
NO CHANGE
Target $72
BARD
Neutral
Amdocs short raises fair questions, but many have reasonable answers, says Baird
Baird analyst William Power said the authors of the short report about Amdocs that was published last week raised "a number of fair questions," though he said most of them aren't new and many have reasonable answers. While total receivable and unbilled receivable DSOs being at all-time highs is not ideal, the fact is also not new and he believes the higher DSOs are tied to recent transformation deals that utilize percentage of completion accounting and include staggered milestones. Power keeps a Neutral rating on Amdocs and said more disclosures around several items, including higher unbilled receivables, receivables factoring, and M&A revenue impacts, would be welcome, adding that he "would not be surprised by at least a trading bounce" given the company's opportunity to address the questions and the stock's trough valuation.
01/10/19
JPMS
01/10/19
NO CHANGE
JPMS
Neutral
Ericsson restructuring of BSS a 'slight positive' for Amdocs, says JPMorgan
After Ericsson (ERIC) announced that it will be taking about $685M in restructuring charges in the fourth quarter to reshape its Business Support System, or BSS, business, JPMorgan analyst Jackson Ader called the news a "slight positive" for Amdocs (DOX). Ericsson's announcement gives more credence to Amdocs' contention that it has competed well against the equipment providers in the BSS space, it shows that the BSS market is strategic enough to warrant increased focus, and it likely gives Amdocs a leg up in the early stages of the 5G rollout, Ader tells investors. He maintains a Neutral rating on Amdocs shares.
LM Legg Mason
$34.67

1.415 (4.26%)

02/05/19
02/05/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Covanta (CVA) upgraded to Buy from Neutral at Goldman Sachs with analyst Brian Lee saying he expects near-term U.K. project pipeline catalysts to highlight the company's medium-to-long term growth potential. 2. Booking Holdings (BKNG) upgraded to Buy from Hold at Deutsche Bank with analyst Lloyd Walmsley saying Booking's room night growth can accelerate in 2019 as the company "leans back into marketing channels," and this can drive multiple expansion. 3. Regenxbio (RGNX) upgraded to Strong Buy from Outperform at Raymond James with analyst Reni Benjamin saying his recent talks with management gave him added information on RGX-314 in patients with wet age-related macular degeneration and an update on the company's other gene therapy programs. 4. Legg Mason (LM) upgraded to Buy from Neutral at Citi. 5. Nine Energy Services (NINE) upgraded to Buy from Hold at Tudor Pickering. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/05/19
WELS
02/05/19
NO CHANGE
Target $34
WELS
Outperform
Legg Mason price target raised to $34 from $29 at Wells Fargo
Wells Fargo analyst Christopher Harris raised his price target for Legg Mason to $34 from $29, while reiterating an Outperform rating on the shares. The company's Q3 was quite noisy because of various charges, but the bigger news was the unveiled plan to implement a new operating platform expected to produce material cost savings, he notes.
02/05/19
SBSH
02/05/19
UPGRADE
SBSH
Buy
Legg Mason upgraded to Buy from Neutral at Citi
Citi analyst Citi analyst William Katz upgraded Legg Mason to Buy.
05/14/19
RBCM
05/14/19
NO CHANGE
Target $39
RBCM
Outperform
Legg Mason price target raised to $39 from $35 at RBC Capital
RBC Capital analyst Kenneth Lee raised his price target on Legg Mason to $39 to reflect the upward drift in its peer group multiples since his last revision. The analyst also notes that the company's Q4 earnings were "in-line" and reduces his FY20 EPS outlook by 12c to $3.25 given his expected impact from its strategic restructuring and assumption of no buybacks this year, but keeps his Outperform rating on Legg Mason shares.
SUNW Sunworks
$1.27

0.03 (2.42%)

08/14/18
CHDN
08/14/18
DOWNGRADE
CHDN
Neutral
Sunworks downgraded to Neutral from Buy at Chardan
A Agilent
$75.98

2.13 (2.88%)

02/21/19
DBAB
02/21/19
NO CHANGE
Target $90
DBAB
Buy
Agilent price target raised to $90 from $85 at Deutsche Bank
Deutsche Bank analyst Dan Leonard raised his price target for Agilent Technologies to $90 and reiterates a Buy rating on the shares following the company's fiscal Q1 results and a fiscal 2019 earnings guidance increase. The analyst continues to believe Agilent has more opportunities for growth, margin expansion, and capital deployment than peers.
03/15/19
UBSW
03/15/19
INITIATION
Target $92
UBSW
Buy
Agilent initiated with a Buy at UBS
UBS analyst Daniel Brennan started Agilent Technologies with a Buy rating and $92 price target. The analyst says stronger revenue growth coupled with rising incremental margins support his earnings forecasts being 2%-3% ahead of consensus. Further, "more aggressive" acquisition activity or share buybacks could drive "material further" earnings upside, Brennan tells investors in a research note. He believes Agilent has "significant balance sheet optionality."
02/21/19
BARD
02/21/19
NO CHANGE
Target $82
BARD
Outperform
Agilent price target raised to $82 from $77 at Baird
Baird analyst Catherin Ramsey-Schulte raised her price target on Agilent to $82 from $77 following Q4 results. The analyst said the shares may be weak following the report given the stock's recent run up and the weakness in LSAG growth. She believes the underlying business remains healthy and continues to see upside from end market strength, new product introductions, and potential incremental capital deployment. Ramsey-Schulte reiterated her Outperform rating on Agilent shares.
03/26/19
COWN
03/26/19
NO CHANGE
Target $90
COWN
Outperform
Agilent price target raised to $90 from $80 at Cowen
Cowen analyst Doug Schenkel maintained an Outperform rating on Agilent and raised his price target to $90 from $80 after hosting meetings with management. In a research note to investors, Schenkel says he came away from the meetings with incremental confidence in the company's ability to continue posting above-peer average top and bottom line growth in the near- and long-term. He believes shares are worth $(0, and could see further upside as management continues to execute relative to expectations.
FSM Fortuna Silver Mines
$2.86

-0.065 (-2.22%)

03/14/19
03/14/19
UPGRADE

Buy
Fortuna Silver Mines upgraded to Buy on valuation at Canaccord
As previously reported, Canaccord analyst Dalton Baretto upgraded Fortuna Silver Mines to Buy from Hold, with a C$5.50 price target, after the company reported Q4 results. The analyst cited the 16% implied return to his price target.
03/14/19
ADAM
03/14/19
UPGRADE
ADAM
Buy
Fortuna Silver Mines upgraded to Buy from Hold at Canaccord
03/05/19
CIBC
03/05/19
DOWNGRADE
CIBC
Neutral
Fortuna Silver Mines downgraded to Neutral from Outperformer at CIBC
02/20/19
ADAM
02/20/19
DOWNGRADE
ADAM
Hold
Fortuna Silver Mines downgraded to Hold from Buy at Canaccord
NEWR New Relic
$106.89

3.94 (3.83%)

02/07/19
DADA
02/07/19
NO CHANGE
Target $125
DADA
Buy
New Relic price target raised to $125 from $105 at DA Davidson
DA Davidson analyst Rishi Jaluria raised his price target on New Relic to $125 and kept his Buy rating after its strong Q3 results driven by the "upside in revenue per paid business account" of over $29K - above the consensus of $27.8K. The analyst adds that the company's cross-selling efforts remained strong and maintains his view of New Relic as one of "prime beneficiaries of the ongoing trend of digital transformation".
02/07/19
WEDB
02/07/19
NO CHANGE
Target $124
WEDB
Outperform
New Relic price target raised to $124 from $116 at Wedbush
Wedbush analyst Steve Koenig raised his price target for New Relic to $124 from $116 after the company posted its biggest revenue beat to date, and guided FY19 revenue up by a solid $6M. While Koenig notes that some analysts expressed disappointment that Q4 deferred revenue guidance was up quarter over quarter in the low-20% range, he is "not concerned," as the guidance beats his target, and he expects some upside. The analyst does not expect further upward rerating of multiples, but healthy growth with modest deceleration provides a good opportunity for further stock appreciation. He reiterates an Outperform rating on the shares.
02/27/19
WEDB
02/27/19
NO CHANGE
Target $124
WEDB
Outperform
New Relic added to Best Ideas List at Wedbush
Wedbush analyst Steve Koenig added New Relic to his firm's Best Ideas List, saying he is bullish on it based on growing enterprise penetration and a promising setup heading into FY20/March. Per his proprietary analysis, New Relic has now penetrated over 50% of the Fortune 100 and is increasing its lead in the cloud, putting it in a good position to claim overall leadership in the application performance management market as application development shifts to the cloud. The analyst expects continued upward revisions to consensus estimates throughout FY20. Koenig reiterates an Outperform rating and $124 price target on the shares.
02/07/19
OPCO
02/07/19
NO CHANGE
Target $125
OPCO
Outperform
New Relic price target raised to $125 from $110 at Oppenheimer
Oppenheimer analyst Ittai Kidron raised his price target for New Relic to $125 from $110 after the company delivered another "strong" quarter ahead of expectations, driven by steady execution, broadbased product demand, and increased large deal activity. The analyst sees a long runway for growth as New Relic focuses on driving larger deal sizes and multi-product use with larger customers. He is also positive on New Relic's acquisition of SignifAI, which adds event intelligence and AI/ML capabilities that will strengthen New Relic's ability to provide end-to-end and contextual visibility in a single-platform. Kidron reiterates an Outperform rating on the shares.
EGHT 8x8, Inc.
$23.73

0.245 (1.04%)

10/30/18
SRCH
10/30/18
INITIATION
SRCH
Hold
8x8, Inc. initiated with a Hold at Summit Insights
Summit Insights initiated 8x8, Inc with a Hold and $20 price target.
10/10/18
WBLR
10/10/18
INITIATION
WBLR
Outperform
8x8, Inc. assumed with an Outperform at William Blair
William Blair analyst Jim Breen assumed coverage of 8x8, Inc. with an Outperform rating.
03/11/19
GUGG
03/11/19
INITIATION
Target $20
GUGG
Neutral
8x8, Inc. initiated with a Neutral at Guggenheim
Guggenheim analyst Nandan Amladi started 8x8, Inc. with a Neutral rating and $20 price target. The analyst likes the company's long-term story but wants to see "more consistent execution" before getting more constructive on the shares.
01/03/19
SPHN
01/03/19
INITIATION
Target $24
SPHN
Overweight
8x8, Inc. initiated with an Overweight at Stephens
Stephens analyst Dmitry Netis started 8x8, Inc. with an Overweight rating and $24 price target. The company is entering the second half of fiscal 2019 with "sustainable momentum" in large customer bookings and an attractive valuation, which creates a favorable risk/reward profile, Netis tells investors in a research note. He says his favorable thesis is supported by a new product cycle helped by the release of the X Series product bundle.
VIRT Virtu Financial
$24.30

-0.56 (-2.25%)

01/04/19
GSCO
01/04/19
UPGRADE
Target $120
GSCO
Buy
Virtu Financial upgraded to Buy from Neutral at Goldman Sachs
Goldman Sachs analyst Alexander Blostein upgraded Virtu Financial to Buy from Neutral with a price target of $29. The analyst cites the "cyclical recovery in volatility" supporting higher rates of growth for Virtu's revenue and earnings. Blostein also expects the company's earnings to be amplified by the accretion from its recent ITG deal, modeling FY19 EPS at $1.95. The analyst anticipates that over the longer term, "further consolidation in the market-making and agency execution space" should remain favorable amid subsiding cost pressures and higher efficiencies across the capital market ecosystem.
01/04/19
MSCO
01/04/19
NO CHANGE
MSCO
Morgan Stanley says buy TD Ameritrade ahead of earnings, negative on Virtu
Morgan Stanley analyst Michael Cyprys lowered his Q4 EPS estimates by 11% for the Asset Manager and Broker group given that the S&P 500 fell nearly 14% in the quarter, upending what had been a positive year for equity markets up until that point. For 2019, he favors the discount brokers - TD Ameritrade (AMTD), E-Trade (ETFC) and Charles Schwab (SCHW) - given their more defensive earnings profiles. Ahead of the Q4 earnings season he sees TD Ameritrade as "compelling" given its greater skew to trading revenues among the eBrokers, greater derivative mix and rising client cash levels, Cyprys tells investors. He also views concerns around commission price cuts as overdone as doe not expect Charles Schwab to cut, the analyst added. Ahead of Q4 reporting, Cyprys is negative on Virtu Financial (VIRT), as he thinks expectations are too high and notes the stock has recently outperformed.
10/05/18
SBSH
10/05/18
NO CHANGE
SBSH
Neutral
Citi views potential ITG deal as favorable for Virtu Financial
A possible acquisition of Investment Technology Group (ITG) by Virtu Financial (VIRT), as reported yesterday by Bloomberg, points to "solid upside," Citi analyst Ben Herbert tell investors in a research note. The analyst views the potential deal favorably for Virtu given his belief that the company's standalone earnings growth may remain challenged against the current environment. His initial pass at potential deal accretion indicates $3.50 per share of upside for Virtu. Herbert keeps a Hold rating on Virtu shares.
09/19/18
09/19/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Aerpio Pharmaceuticals (ARPO) initiated with a Buy at Guggenheim. 2. Vocera (VCRA) initiated with a Buy at Jefferies. 3. Veoneer (VNE) initiated with a Neutral at Buckingham. 4. Virtu Financial (VIRT) initiated with a Neutral at Compass Point. 5. Internap (INAP) initiated with a Buy at SunTrust. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
JKS JinkoSolar
$17.71

0.3 (1.72%)

03/06/19
VERF
03/06/19
NO CHANGE
VERF
Sell
JinkoSolar a 'screaming short' given debt obligations, says Vertical Group
Vertical Group analyst Gordon Johnson said in an email that he believes JinkoSolar is a "screaming short" given that the company has not denied they are obligated for Jinko Power's "suspended" $299M bond offering, replying only that they "believe Jinko Power will be able to raise debt this year." In his email, Johnson added: "If they're wrong, which they were when Jinko Power tried to issue debt earlier this year, you're talking about an unknown debt liability the size of JKS' market cap (yes, you heard that right)." Johnson has a Sell rating on JinkoSolar shares.
02/04/19
ROTH
02/04/19
UPGRADE
ROTH
Buy
JinkoSolar upgraded to Buy from Neutral at Roth Capital
02/04/19
02/04/19
UPGRADE
Target $20

Buy
JinkoSolar upgraded to Buy at Roth Capital on global demand strength
As previously reported, Roth Capital analyst Philip Shen upgraded JinkoSolar to a Buy from a Neutral on global demand strength ex-China. The analyst expects tight module supply to drive pricing modestly higher in the U.S. and around the world. With costs likely muted/low and ASPs moving up, Shen takes up his 2019/2020 estimates and sees greater earnings power ahead. The analyst also raised his price target on the shares to $20 from $11.50 as he continues to see upside for the stock.
12/19/18
12/19/18
INITIATION

JinkoSolar initiated with a Sell at Williams Research
Williams Research Partners started JinkoSolar with a Sell rating and $1 price target.
WMC Western Asset Mortgage
$10.57

0.045 (0.43%)

03/18/19
03/18/19
INITIATION

Fly Intel: Top analyst initiations
Catch up on today's top analyst initiations with this list compiled by The Fly: 1. Western Asset Mortgage (WMC) initiated with a Market Perform at Keefe Bruyette. 2. Cars.com (CARS) initiated with a Neutral at Goldman Sachs. 3. Super League Gaming (SLGG) initiated with an Outperform at Northland. 4. Arcus Biosciences (RCUS) initiated with a Buy at BTIG, while Momenta (MNTA) initiated with a Neutral. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
03/17/19
KBWI
03/17/19
INITIATION
Target $10.5
KBWI
Market Perform
Western Asset Mortgage initiated with a Market Perform at Keefe Bruyette
Keefe Bruyette analyst Eric Hagen started Western Asset Mortgage with a Market Perform rating and $10.50 price target.

TODAY'S FREE FLY STORIES

TEVA

Teva

$10.86

-0.18 (-1.63%)

12:11
05/26/19
05/26
12:11
05/26/19
12:11
Hot Stocks
Teva reaches $85M agreement with State of Oklahoma »

Teva Pharmaceuticals USA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ESLT

Elbit Systems

$141.85

1.33 (0.95%)

12:08
05/26/19
05/26
12:08
05/26/19
12:08
Hot Stocks
Elbit Systems awarded $127M contract to provide tactical radio system »

Elbit Systems announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

ADM

Archer Daniels

$39.17

-0.03 (-0.08%)

12:05
05/26/19
05/26
12:05
05/26/19
12:05
Hot Stocks
Archer Daniels expands recall of Baker's Corner All Purpose Flour 5lb bags »

ADM Milling is recalling…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

JCP

J.C. Penney

$0.93

0.022 (2.42%)

, DDS

Dillard's

$56.57

0.25 (0.44%)

13:29
05/25/19
05/25
13:29
05/25/19
13:29
Periodicals
Target stock triumphs in brutal week for retail, Barron's says »

Earnings season has been…

JCP

J.C. Penney

$0.93

0.022 (2.42%)

DDS

Dillard's

$56.57

0.25 (0.44%)

KSS

Kohl's

$51.11

-0.04 (-0.08%)

JWN

Nordstrom

$33.50

-0.31 (-0.92%)

M

Macy's

$21.00

-0.27 (-1.27%)

TGT

Target

$81.57

2.17 (2.73%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Jun

JPM

JPMorgan

$109.78

1.14 (1.05%)

, AKZOY

AkzoNobel

$0.00

(0.00%)

13:24
05/25/19
05/25
13:24
05/25/19
13:24
Periodicals
Microsoft, JPMorgan among dividend champions, Barron's says »

Among the companies that…

JPM

JPMorgan

$109.78

1.14 (1.05%)

AKZOY

AkzoNobel

$0.00

(0.00%)

XOM

Exxon Mobil

$74.12

0.33 (0.45%)

MSFT

Microsoft

$126.23

0.04 (0.03%)

CMWAY

Commonwealth Bank of Australia

$0.00

(0.00%)

SIEGY

Siemens

$0.00

(0.00%)

T

AT&T

$32.29

0.15 (0.47%)

RDS.A

Royal Dutch Shell

$63.29

0.84 (1.35%)

RHHBY

Roche

$0.00

(0.00%)

NVS

Novartis

$87.49

3.03 (3.59%)

BHP

BHP Group

$52.47

1.18 (2.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

  • 29

    May

  • 29

    May

  • 31

    May

  • 03

    Jun

  • 03

    Jun

  • 03

    Jun

  • 05

    Jun

  • 08

    Jun

  • 10

    Jun

  • 10

    Jun

  • 11

    Jun

  • 11

    Jun

  • 12

    Jun

  • 20

    Jun

  • 23

    Jun

  • 16

    Jul

  • 24

    Jul

  • 06

    Aug

  • 18

    Aug

  • 19

    Aug

  • 02

    Sep

  • 04

    Nov

GM

General Motors

$35.13

0.01 (0.03%)

, TSLA

Tesla

$190.80

-4.7 (-2.40%)

13:19
05/25/19
05/25
13:19
05/25/19
13:19
Periodicals
Tesla stock in trouble, Barron's says »

Tesla (TSLA) stock is the…

GM

General Motors

$35.13

0.01 (0.03%)

TSLA

Tesla

$190.80

-4.7 (-2.40%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Jun

  • 05

    Jun

  • 11

    Jun

  • 01

    Aug

RNLSY

Renault

$0.00

(0.00%)

13:14
05/25/19
05/25
13:14
05/25/19
13:14
Periodicals
Renault stock may rally, Barron's says »

Shares of French auto…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FMC

FMC Corporation

$70.88

-0.47 (-0.66%)

, DWDP

DowDuPont

$31.10

0.16 (0.52%)

13:11
05/25/19
05/25
13:11
05/25/19
13:11
Periodicals
DowDuPont spinoff a new agriculture stock, FMC safer bet, Barron's says »

The crop-protection and…

FMC

FMC Corporation

$70.88

-0.47 (-0.66%)

DWDP

DowDuPont

$31.10

0.16 (0.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 25

    Jun

MGM

MGM Resorts

$25.55

0.19 (0.75%)

13:03
05/25/19
05/25
13:03
05/25/19
13:03
Periodicals
MGM Resorts looks like an attractive gambling play, Barron's says »

MGM Resorts (MGM) stock…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

PYPL

PayPal

$109.82

-0.09 (-0.08%)

, AXP

American Express

$119.52

1.07 (0.90%)

12:30
05/25/19
05/25
12:30
05/25/19
12:30
Periodicals
Big tech failed to dethrone credit cards, Barron's says »

Rather than being cut out…

PYPL

PayPal

$109.82

-0.09 (-0.08%)

AXP

American Express

$119.52

1.07 (0.90%)

MA

MasterCard

$251.40

1.57 (0.63%)

V

Visa

$162.72

1.2 (0.74%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 03

    Jun

  • 05

    Jun

  • 06

    Jun

  • 11

    Jun

  • 25

    Jun

  • 13

    Nov

GOOG

Alphabet

$1,132.99

-7.56 (-0.66%)

, GOOGL

Alphabet Class A

$1,138.90

-5.98 (-0.52%)

07:20
05/25/19
05/25
07:20
05/25/19
07:20
On The Fly
Week in review: How Trump's policies moved stocks »

Catch up on the top…

GOOG

Alphabet

$1,132.99

-7.56 (-0.66%)

GOOGL

Alphabet Class A

$1,138.90

-5.98 (-0.52%)

MSFT

Microsoft

$126.23

0.04 (0.03%)

AMBA

Ambarella

$38.28

1.07 (2.88%)

ON

ON Semiconductor

$17.68

-0.235 (-1.31%)

NKE

Nike

$82.12

-0.51 (-0.62%)

ADDYY

Adidas

$0.00

(0.00%)

UAA

Under Armour

$23.54

0.075 (0.32%)

UA

Under Armour

$20.91

0.08 (0.38%)

FL

Foot Locker

$44.39

-8.455 (-16.00%)

VMC

Vulcan Materials

$126.28

1.25 (1.00%)

FLR

Fluor

$29.04

0.18 (0.62%)

ACM

Aecom

$31.56

-0.03 (-0.09%)

X

U.S. Steel

$13.63

-0.08 (-0.58%)

AKS

AK Steel

$2.00

-0.155 (-7.21%)

NUE

Nucor

$51.12

-0.27 (-0.53%)

DDAIF

Daimler AG

$0.00

(0.00%)

FCAU

Fiat Chrysler

$12.85

0.11 (0.86%)

F

Ford

$9.83

-0.02 (-0.20%)

GM

General Motors

$35.13

0.01 (0.03%)

HMC

Honda

$25.45

0.175 (0.69%)

NSANY

Nissan

$0.00

(0.00%)

TM

Toyota

$118.54

1.16 (0.99%)

VWAGY

Volkswagen

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

  • 03

    Jun

  • 03

    Jun

  • 04

    Jun

  • 04

    Jun

  • 05

    Jun

  • 06

    Jun

  • 08

    Jun

  • 10

    Jun

  • 10

    Jun

  • 11

    Jun

  • 12

    Jun

  • 13

    Jun

  • 19

    Jun

  • 19

    Jun

  • 23

    Jun

  • 09

    Jul

  • 24

    Jul

  • 31

    Jul

  • 01

    Aug

  • 06

    Aug

  • 23

    Oct

  • 27

    Oct

UBER

Uber

$41.40

0.94 (2.32%)

17:49
05/24/19
05/24
17:49
05/24/19
17:49
Hot Stocks
Uber board director Ryan Graves intends to resign »

According to a regulatory…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

APTO

Aptose Biosciences

$2.01

0.03 (1.52%)

17:46
05/24/19
05/24
17:46
05/24/19
17:46
Syndicate
Aptose Biosciences files for $40M at-the-market common stock offering »

Piper Jaffray and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Jun

TRNX

Taronis Technologies

$0.48

0.004 (0.84%)

17:26
05/24/19
05/24
17:26
05/24/19
17:26
Syndicate
Breaking Syndicate news story on Taronis Technologies »

Taronis Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

USEG

U.S. Energy

$0.45

0.0373 (9.10%)

17:25
05/24/19
05/24
17:25
05/24/19
17:25
Hot Stocks
U.S. Energy discloses Nasdaq notice regarding delayed 10-Q filing »

U.S. Energy announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$179.03

-0.64 (-0.36%)

17:22
05/24/19
05/24
17:22
05/24/19
17:22
Periodicals
Apple sued over allegedly selling users' iTunes data, Bloomberg says »

Apple is being sued by…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Jun

SPCB

SuperCom

$1.17

-0.005 (-0.43%)

17:21
05/24/19
05/24
17:21
05/24/19
17:21
Hot Stocks
SuperCom discloses Nasdaq notice regarding delayed 20-F filing »

SuperCom received a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

USEG

U.S. Energy

$0.45

0.0373 (9.10%)

17:20
05/24/19
05/24
17:20
05/24/19
17:20
Hot Stocks
U.S. Energy receives noncompliance notice from Nasdaq »

U.S. Energy announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MYOV

Myovant Sciences

$12.39

-0.465 (-3.62%)

17:18
05/24/19
05/24
17:18
05/24/19
17:18
Syndicate
Breaking Syndicate news story on Myovant Sciences »

Myovant Sciences files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MYOV

Myovant Sciences

$12.39

-0.465 (-3.62%)

17:17
05/24/19
05/24
17:17
05/24/19
17:17
Syndicate
Breaking Syndicate news story on Myovant Sciences »

Myovant Sciences files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVS

Novartis

$87.49

3.03 (3.59%)

, QGEN

Qiagen

$38.22

-0.255 (-0.66%)

16:57
05/24/19
05/24
16:57
05/24/19
16:57
Hot Stocks
Qiagen launches diagnostic for PIK3CA biomarkers in breast cancer »

Qiagen (QGEN) announced…

NVS

Novartis

$87.49

3.03 (3.59%)

QGEN

Qiagen

$38.22

-0.255 (-0.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    May

  • 31

    May

  • 20

    Jun

  • 06

    Aug

AVH

Avianca

$3.96

0.91 (29.84%)

16:56
05/24/19
05/24
16:56
05/24/19
16:56
Periodicals
ANAC suspends flights, operations of Avianca Brasil, Reuters reports »

Brazil's ANAC said…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$179.03

-0.64 (-0.36%)

16:53
05/24/19
05/24
16:53
05/24/19
16:53
Periodicals
Apple acquires startup Tueo Health, CNBC reports »

Apple has bought Tueo…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Jun

SHSP

SharpSpring

$16.37

-0.24 (-1.44%)

16:52
05/24/19
05/24
16:52
05/24/19
16:52
Syndicate
Breaking Syndicate news story on SharpSpring »

SharpSpring files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Jun

CREG

China Recycling Energy

$0.48

0.005 (1.05%)

16:41
05/24/19
05/24
16:41
05/24/19
16:41
Syndicate
Breaking Syndicate news story on China Recycling Energy »

China Recycling Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.